Omaron, tablets 90 pcs

Combined medicine with pronounced antihypoxic, nootropic and vasodilator effect.

Piracetam activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating glucose utilization by cells and increasing their resistance to hypoxia;

improves inter-neuronal transmission in the central nervous system, improves regional blood flow in the ischemic area.

Cinnarizine is a selective blocker of “slow” calcium channels, reduces the entry of calcium ions into cells and reduces its content in the plasma membrane depot, reduces the tone of arteriolar smooth muscle,

reduces their response to biogenic vasoconstrictors (adrenaline, noradrenaline, dopamine, angiotensin II, vasopressin, serotonin).

It has a vasodilator effect (especially on brain vessels, increasing the antihypoxic effect of piracetam), without a significant effect on blood pressure.

It has moderate antihistamine activity, decreases the excitability of the vestibular system, reduces the tone of the sympathetic nervous system.

Increases elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity.

Absorption. After oral administration piracetam and cinnarizine are quickly and almost completely absorbed in the gastrointestinal tract. Bioavailability of piracetam is about 100%.

Maximum concentration (Cmax) of piracetam is reached 0.5-1 hour after intake. The maximum concentration of cinnarizine in plasma is reached after 1-3 hours. Bioavailability of cinnarizine increases in acidic environment.

Distribution. Piracetam does not bind with blood plasma proteins. The volume of distribution is about 0.6 l/kg.

Passes through the blood-brain and placental barriers, to all organs and tissues, as well as through filter membranes used in hemodialysis.

In animal studies it was found that piracetam selectively accumulates in cortical tissues, mainly in the frontal, parietal and occipital lobes, cerebellum and basal ganglia.

Cinnarizine. Binding with plasma proteins is 91%. In 1-4 hours after oral administration it is found in liver, kidneys, heart, lungs, spleen and brain.

Metabolism. Piracetam is virtually unmetabolized in the body.

Cinnarizine is actively and completely metabolized by dealkylation; the metabolic process begins 30 minutes after oral administration.

Excretion. Piracetam. More than 95% of the oral dose is eliminated unchanged by the kidneys by renal filtration within 30 hours.

Renal clearance of piracetam in healthy volunteers is 86 ml/min.

Half-life (T1/2) is 4-5 hours from blood plasma and 8.5 hours from cerebrospinal fluid.

In patients with renal insufficiency T1/2 is prolonged. In patients with hepatic insufficiency pharmacokinetics of piracetam does not change.

Cinnarizine is excreted from the body as metabolites (1/3 – by kidneys, 2/3 – through intestine), T1/2 – about 4 hours.

Indications

Active ingredient

Composition

Active ingredients:

Piracetam 400 mg;

Cinnarizine 25 mg;

Auxiliary substances:

Lactose monohydrate 23.5 mg;

Magnesium hydroxycarbonate pentahydrate 46.8 mg;

Povidone (collidon 30) 3.9 mg;

p> Colloidal silicon dioxide (aerosil A-380) 5.2 mg,

Calcium stearate monohydrate 5.2 mg;

Crospovidone (collidon SL-M) 10.4 mg.

How to take, the dosage

Adults are prescribed 1-2 tablets. 3 times a day for 1-3 months depending on the severity of the disease;

Children – 1-2 tablets.

In children – 1-2 tablets 1-2 times a day. The drug should not be used for more than 3 months.

Interaction

Concomitant use may increase the sedative effect of agents that depress the central nervous system, as well as ethanol, nootropics and antihypertensives.

Vasodilators increase the effect of the drug.

It improves tolerability of antipsychotic drugs and tricyclic antidepressants.

When used concomitantly, piracetam increases the central effects of thyroid hormones (tremor, restlessness, irritability, sleep disturbances are possible); it may increase the effect of oral anticoagulants.

Directions for use

Special Instructions

In long-term use, monitoring of liver and renal function is recommended (especially in patients with chronic renal failure).

During treatment, patients with arterial hypotension may have a greater decrease in blood pressure.

The use of alcohol during treatment is not recommended.

The results of doping tests and allergic skin tests may be distorted; the drug should be discontinued 4 days before the study.

Impact on driving and operating machinery

When using the drug during treatment, caution should be exercised while driving motor transport and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Synopsis

Contraindications

Side effects

Central and peripheral nervous system disorders: motor disinhibition, irritability, somnolence, depression, asthenia, headache. In single cases dizziness, ataxia, worsening of epilepsy, extrapyramidal disorders, tremor, unsteadiness, decreased ability to concentrate, insomnia, agitation, anxiety, hallucinations, increased sexuality have been reported.

Cardiovascular system: decreased or increased blood pressure.

Digestive system disorders: dyspeptic phenomena, feeling of dry mouth; in single cases – nausea, vomiting, diarrhea, abdominal pain, cholestatic jaundice.

Skin disorders: dermatitis, itching, skin rash in single cases.

Metabolism: weight gain.

Allergic reactions: angioedema.

Others: increased sweating; in single cases – lupus-like syndrome, lichen planus.

Overdose

Symptoms of overdose mainly due to the m-cholin-blocking activity of cinnarizine include: impaired consciousness, vomiting, extrapyramidal symptoms, decreased blood pressure. Bloody diarrhea and abdominal pain were observed after oral administration of piracetam at a dose of 75 g.

Treatment: there is no specific antidote. In case of overdose gastric lavage and administration of activated charcoal, symptomatic and supportive therapy are necessary. The effectiveness of hemodialysis for piracetam is 50-60%.

Pregnancy use

The drug is contraindicated in pregnancy and lactation.

Similarities